サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1402526

欧州の肺がんスクリーニング市場の2030年までの予測：地域別分析 - がんタイプ、技術、年齢層、エンドユーザー別

Europe Lung Cancer Screening Market Forecast to 2030 - Regional Analysis - by Cancer Type, Technology, Age Group (50 & Older and Below 50), and End User (Hospitals, Diagnostic Centers, and Others)
出版日: | 発行: The Insight Partners | ページ情報: 英文 131 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.58円
欧州の肺がんスクリーニング市場の2030年までの予測：地域別分析 - がんタイプ、技術、年齢層、エンドユーザー別
出版日: 2023年11月01日
発行: The Insight Partners
ページ情報: 英文 131 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

欧州の肺がんスクリーニング市場は、2022年の5億9,325万米ドルから2030年には10億9,099万米ドルに成長すると予測されています。2022年から2030年までのCAGRは7.9%と推定されます。

肺がん罹患率の上昇が欧州の肺がんスクリーニング市場に拍車をかける。

肺がんは、世界中で主要な死亡原因のひとつです。肺がんスクリーニングは、がん予防アプローチの重要な要素です。肺がん患者の予後は、早期に診断された方が良好であるため、肺がんのリスクが高い人は、肺にがんができるのを発見するために定期的な検診を受けるよう促されています。

がん専門誌『Annals of Oncology』が行った調査によると、EU地域では2023年に約1,261,990人のがん患者が死亡すると予想されています。肺がんの死亡率は1％以上増加し、10万人あたり13.6人となります。英国の女性の方がEUの女性よりも早く喫煙を始めたため、英国の女性の肺がんによる死亡率は13.8％減少するが、それでも10万人当たり16.2人という死亡率はEUの女性よりも高いです。英国では現在、肺がんによる死亡者数は10万人当たり13.5人の乳がんによる死亡者数を上回っています。

研究者らが、英国に加えてEU5カ国の肺がん死亡率を特に調査したところ、最も人口の多い6カ国（フランス、ドイツ、イタリア、ポーランド、スペイン）では男性の死亡率が減少する一方、フランス、イタリア、スペインでは女性の死亡率がそれぞれ約14％、5.6％、5％増加することがわかった。研究者らは、様々な年齢層の女性において、肺がんによる予想死亡率は、25歳から64歳では減少するが、65歳から75歳以上では増加し、全体としては増加することを発見しました。また、国立生物工学情報センター（NCBI）によると、イタリアでは毎年、～41,000人が新たに肺がんと診断され、34,000人が死亡しています。このように、世界の肺がん罹患率の上昇が肺がんスクリーニングプログラムの開始に寄与しており、これが市場成長の原動力となっています。

欧州の肺がんスクリーニング市場概要

欧州の肺がんスクリーニング市場は、ドイツ、英国、フランス、イタリア、スペイン、その他欧州に区分されます。この地域の成長は、肺がん罹患率の増加や、人々の肺がんスクリーニング・診断に対する意識の高まりなど、さまざまな要因によるものです。また、検診に対する政府支援の高まりが、市場のさらなる成長につながっています。

肺がんの有病率の増加により、早期発見のための検診が非常に重要になっています。肺がんスクリーニングは、長年の喫煙者で肺がんに関連する症状のない高齢者に推奨されています。医師は検診に低線量コンピューター断層撮影（LDCT）スキャンやX線検査を用います。

2022年6月にJournal of Thoracic Oncology誌に掲載された「Lung Cancer in Germany（ドイツにおける肺がん）」と題する論文によると、ドイツではがんが死因の第2位で、全死亡者の25％を占めています。男性では、肺がんは心血管疾患に次いで第2位で、全死因死亡の6.5％を占める。年齢標準化罹患率は男性で52.1、女性で32.7（10万人当たり）であり、肺がんは男性で第2位、女性で第3位である（新たに診断されたがんのそれぞれ13.3％、9.4％を占める）。がんと診断される平均年齢は70歳（男性）、69歳（女性）であり、全患者の52％がステージIVです。女性と男性の罹患率は、喫煙習慣の長期的な変化により1990年代以降収束しています。現在、ドイツでは男性の4人に1人（27.0％）、女性の5人に1人（20.8％）が定期的に喫煙しています。

欧州の肺がんスクリーニング市場の収益と2030年までの予測（金額）

欧州の肺がんスクリーニング市場のセグメンテーション

欧州の肺がんスクリーニング市場は、がん種、技術、年齢層、エンドユーザー、国別に区分されます。

がんタイプに基づき、欧州の肺がんスクリーニング市場は非小細胞肺がん（NSCLC）、小細胞肺がんに区分されます。2022年の欧州の肺がんスクリーニング市場では、非小細胞肺がん（NSCLC）セグメントが大きなシェアを占めています。

技術に基づき、欧州の肺がんスクリーニング市場は胸部X線、低線量コンピュータ断層撮影（LDCT）、リキッドバイオプシー、その他に区分されます。低線量コンピュータ断層撮影（LDCT）セグメントが2022年の欧州の肺がんスクリーニング市場で最大のシェアを占めました。

年齢層に基づき、欧州の肺がんスクリーニング市場は50歳以上と50歳未満に区分されます。50歳以上セグメントは2022年に欧州の肺がんスクリーニング市場でより大きなシェアを占めました。

エンドユーザーに基づき、欧州の肺がんスクリーニング市場は病院、診断センター、その他に区分されます。病院セグメントは2022年に欧州の肺がんスクリーニング市場で最大のシェアを占めました。

国別では、欧州の肺がんスクリーニング市場はドイツ、英国、フランス、イタリア、スペイン、その他欧州に区分されます。2022年の欧州の肺がんスクリーニング市場はドイツが独占。

Siemens AG、Koninklijke Philips NV、Canon Inc、Medtronic、GE HealthCare、Nuance Communications Inc、Intelerad Medical Systemsは、欧州の肺がんスクリーニング市場で事業展開している大手企業です。

目次

目次

第1章 イントロダクション

第2章 欧州の肺がんスクリーニング市場：要点

第3章 調査手法

  • 調査範囲
  • 2次調査
  • 1次調査

第4章 欧州の肺がんスクリーニング市場：市場情勢

  • 欧州PEST分析
  • 専門家の見解

第5章 欧州の肺がんスクリーニング市場：主要市場力学

  • 市場促進要因
    • 肺がん罹患率の上昇
  • 市場抑制要因
    • 肺がんスクリーニング検査の高コスト
  • 市場機会
    • 肺がんスクリーニングプログラムの構造化
  • 今後の動向
    • 移動式肺がんスクリーニングトラック
  • 影響分析

第6章 欧州の肺がんスクリーニング市場：欧州分析

  • 欧州の肺がんスクリーニング市場の収益と予測分析

第7章 欧州の肺がんスクリーニング市場-2028年までの収益と予測：がんタイプ別

  • 非小細胞肺がん（NSCLC）
  • 小細胞肺がん

第8章 欧州の肺がんスクリーニング市場分析：技術別

  • 低線量コンピュータ断層撮影（LDCT）
  • 胸部X線
  • リキッドバイオプシー
  • その他

第9章 欧州の肺がんスクリーニング市場分析：年齢層別

  • 50歳以上
  • 50歳未満

第10章 欧州の肺がんスクリーニング市場分析：エンドユーザー別

  • 病院
  • 診断センター
  • その他

第11章 欧州の肺がんスクリーニング市場-2028年までの収益と予測：国別分析

  • 欧州欧州の肺がんスクリーニング市場概要

第12章 欧州の肺がんスクリーニング市場：業界情勢

  • 最近の成長戦略

第13章 企業プロファイル

  • Intelerad Medical Systems
  • Nuance Communications Inc
  • GE HealthCare
  • Medtronic
  • Canon Inc.
  • Koninklijke Philips NV
  • Siemens AG

第14章 付録

図表

List Of Tables

List of Tables

  • Table 1. Germany Europe Lung Cancer Screening Market, by Cancer Type - Revenue and Forecast to 20228 (US$ Million)
  • Table 2. Germany Europe Lung Cancer Screening Market, by Technology - Revenue and Forecast to 2030 (US$ Million)
  • Table 3. Germany Europe Lung Cancer Screening Market, by Age Group - Revenue and Forecast to 2030 (US$ Million)
  • Table 4. Germany Europe Lung Cancer Screening Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 5. UK Europe Lung Cancer Screening Market, by Cancer Type - Revenue and Forecast to 20228 (US$ Million)
  • Table 6. UK Europe Lung Cancer Screening Market, by Technology - Revenue and Forecast to 2030 (US$ Million)
  • Table 7. UK Europe Lung Cancer Screening Market, by Age Group - Revenue and Forecast to 2030 (US$ Million)
  • Table 8. UK Europe Lung Cancer Screening Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 9. France Europe Lung Cancer Screening Market, by Cancer Type - Revenue and Forecast to 20228 (US$ Million)
  • Table 10. France Europe Lung Cancer Screening Market, by Technology - Revenue and Forecast to 2030 (US$ Million)
  • Table 11. France Europe Lung Cancer Screening Market, by Age Group - Revenue and Forecast to 2030 (US$ Million)
  • Table 12. France Europe Lung Cancer Screening Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 13. Italy Europe Lung Cancer Screening Market, by Cancer Type - Revenue and Forecast to 20228 (US$ Million)
  • Table 14. Italy Europe Lung Cancer Screening Market, by Technology - Revenue and Forecast to 2030 (US$ Million)
  • Table 15. Italy Europe Lung Cancer Screening Market, by Age Group - Revenue and Forecast to 2030 (US$ Million)
  • Table 16. Italy Europe Lung Cancer Screening Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 17. Spain Europe Lung Cancer Screening Market, by Cancer Type - Revenue and Forecast to 20228 (US$ Million)
  • Table 18. Spain Europe Lung Cancer Screening Market, by Technology - Revenue and Forecast to 2030 (US$ Million)
  • Table 19. Spain Europe Lung Cancer Screening Market, by Age Group - Revenue and Forecast to 2030 (US$ Million)
  • Table 20. Spain Europe Lung Cancer Screening Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 21. Rest of Europe Lung Cancer Screening Market, by Cancer Type - Revenue and Forecast to 20228 (US$ Million)
  • Table 22. Rest of Europe Lung Cancer Screening Market, by Technology - Revenue and Forecast to 2030 (US$ Million)
  • Table 23. Rest of Europe Lung Cancer Screening Market, by Age Group - Revenue and Forecast to 2030 (US$ Million)
  • Table 24. Rest of Europe Lung Cancer Screening Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 25. Recent Growth Strategies in the Europe Lung Cancer Screening Market
  • Table 26. Glossary of Terms

List Of Figures

List of Figures

  • Figure 1. Europe Lung Cancer Screening Market Segmentation
  • Figure 2. Europe Lung Cancer Screening Market, by Country
  • Figure 3. Europe Lung Cancer Screening Market Overview
  • Figure 4. Non-Small Cell Lung Cancer Segment Held Largest Share of Cancer Type Segment in Europe Lung Cancer Screening Market
  • Figure 5. Asia Pacific Expected to Show Remarkable Growth During Forecast Period
  • Figure 6. Europe: PEST Analysis
  • Figure 7. Experts' Opinion
  • Figure 8. Europe Lung Cancer Screening Market Impact Analysis of Driver and Restraints
  • Figure 9. Europe Lung Cancer Screening Market - Revenue Forecast and Analysis - 2020-2030
  • Figure 10. Europe Lung Cancer Screening Market Revenue Share, by Cancer Type 2022 & 2030 (%)
  • Figure 11. Non-Small Cell Lung Cancer (NSCLC): Europe Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 12. Small Cell Lung Cancer: Europe Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 13. Europe Lung Cancer Screening Market, by Technology, 2022 & 2030 (%)
  • Figure 14. Low-Dose Computed Tomography (LDCT): Europe Lung Cancer Screening Market- Revenue and Forecast to 2030 (US$ Million)
  • Figure 15. Chest X-ray: Europe Lung Cancer Screening Market- Revenue and Forecast to 2030 (US$ Million)
  • Figure 16. Liquid Biopsy: Europe Lung Cancer Screening Market- Revenue and Forecast to 2030 (US$ Million)
  • Figure 17. Others: Europe Lung Cancer Screening Market- Revenue and Forecast to 2030 (US$ Million)
  • Figure 18. Europe Lung Cancer Screening Market, by Age group, 2022 & 2030 (%)
  • Figure 19. & Older: Lung Cancer Screenings Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 20. Below 50: Lung Cancer Screenings Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 21. Europe Lung Cancer Screening Market, by End User, 2022 & 2030 (%)
  • Figure 22. Hospitals: Lung Cancer Screenings Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 23. Diagnostic Centers: Lung Cancer Screenings Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 24. Others: Lung Cancer Screenings Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 25. Europe Lung Cancer Screening Market, by Key Country - Revenue (2022) (US$ Million)
  • Figure 26. Europe Lung Cancer Screening Market Revenue Share, by Country, (2022 & 2030)
  • Figure 27. Germany: Europe Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 28. UK: Europe Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 29. France: Europe Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 30. Italy: Europe Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 31. Spain: Europe Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 32. Rest of Europe: Europe Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
目次
Product Code: BMIRE00029047

The Europe lung cancer screening market is expected to grow from US$ 593.25 million in 2022 to US$ 1,090.99 million by 2030. It is estimated to grow at a CAGR of 7.9% from 2022 to 2030.

Rising Lung Cancer Incidences Fuel Europe lung cancer screening market.

Lung cancer is among one of the main causes of mortality across the world. Lung cancer screening is a critical component of cancer prevention approaches. The prognosis of lung cancer patients is better when the disease is diagnosed early, so people at high risk of lung cancer are prompted to undergo routine checkups to detect the formation of cancerous growth in their lungs.

As per research conducted by the cancer journal Annals of Oncology, around 1,261,990 cancer patients are expected to die in 2023 in the EU region. Lung cancer death rates would increase by over 1% to 13.6 per 100,000. As more UK women started smoking earlier than those in the EU, there will be a 13.8% decrease in the death rate from lung cancer among women in the UK, although the death rate of 16.2 per 100,000 is still higher than among women in the EU. In the UK, lung cancer currently claims more per 100,000 than breast cancer, which claims 13.5 per 100,000.

When the researchers particularly examined lung cancer death rates in five EU nations in addition to the UK, they discovered that while rates are expected to decline for men in the most populous six nations (France, Germany, Italy, Poland, and Spain), they will increase for women in France, Italy, and Spain by about 14%, 5.6%, and 5%, respectively. The researchers discovered that among women in various age groups, expected mortality rates from lung cancer decreased among those between the ages of 25 and 64 but increased among those between the ages of 65 and over 75, leading to an increase overall. Also, according to the National Center for Biotechnology Information (NCBI), each year, ~41,000 new diagnoses of lung cancers and 34,000 deaths are recorded in Italy. Thus, the rising incidence of lung cancer worldwide is contributing to the initiation of lung cancer screening programs, which is, in turn, driving the market growth.

Europe Lung Cancer Screening Market Overview

The Europe lung cancer screening market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. The regional growth is attributed to various factors, such as the increasing incidence of lung cancer and awareness of side lung cancer screening and diagnosis among people. Also, rising government support for screening has led to the further growth of the market.

The increasing prevalence of lung cancer has made its screening extremely important for early detection. Lung cancer screening is suggested for older adults who are long-time smokers and do not have any symptoms related to lung cancer. Physicians use a low-dose computerized tomography (LDCT) scan or X-ray for screening.

According to an article titled "Lung Cancer in Germany," published in the Journal of Thoracic Oncology, in June 2022, cancer is among the second most frequent cause of death in Germany, accounting for 25% of all deaths. In men, lung cancer ranks second after cardiovascular disease, accounting for 6.5% of all-cause mortality. With an age-standardized incidence rate of 52.1 and 32.7 and (per 100,000) in men and women, respectively, lung cancer ranks second in men and third in women (accounting for 13.3% and 9.4% of all newly diagnosed cancers, respectively). The average age of cancer diagnosis is 70 years (men) and 69 years (women); 52% of all patients present with stage IV. The incidence rates in women and men have converged since the 1990s because of long-term changes in smoking habits. Currently, every fourth man (27.0%) and every fifth woman (20.8%) in Germany smokes regularly

Europe Lung Cancer Screening Market Revenue and Forecast to 2030 (US$ Million)

Europe Lung Cancer Screening Market Segmentation

The Europe lung cancer screening market is segmented into cancer type, technology, age group, end user, and country.

Based on cancer type, the Europe lung cancer screening market is segmented into non-small cell lung cancer (NSCLC), and small cell lung cancer. The non-small cell lung cancer (NSCLC) segment held a larger share of the Europe lung cancer screening market in 2022.

Based on technology, the Europe lung cancer screening market is segmented into chest X-ray, low dose computed tomography (LDCT), liquid biopsy, and others. Low dose computed tomography (LDCT) segment held the largest share of the Europe lung cancer screening market in 2022.

Based on age group, the Europe lung cancer screening market is segmented into 50 and older, and below 50. 50 and older segment held the larger share of the Europe lung cancer screening market in 2022.

Based on end user, the Europe lung cancer screening market is segmented into hospital, diagnostic centre, and others. Hospital segment held the largest share of the Europe lung cancer screening market in 2022.

Based on country, the Europe lung cancer screening market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Germany dominated the Europe lung cancer screening market in 2022.

Siemens AG, Koninklijke Philips NV, Canon Inc, Medtronic, GE HealthCare, Nuance Communications Inc, and Intelerad Medical Systems are some of the leading companies operating in the Europe lung cancer screening market.

Reasons to Buy:

  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe Lung Cancer Screening Market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in Europe Lung Cancer Screening Market, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth Europe Market trends and outlook coupled with the factors driving the market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

Table Of Contents

Table of Contents

1. Introduction

  • 1.1 Study Scope
  • 1.2 The Insight Partners Research Report Guidance
  • 1.3 Market Segmentation
    • 1.3.1 Europe Lung Cancer Screening Market - by Technology
    • 1.3.2 Europe Lung Cancer Screening Market - by Cancer Type
    • 1.3.3 Europe Lung Cancer Screening Market - by Age Group
    • 1.3.4 Europe Lung Cancer Screening Market - by End User
    • 1.3.5 Europe Lung Cancer Screening Market - by Country

2. Europe Lung Cancer Screening Market - Key Takeaways

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. Europe Lung Cancer Screening Market - Market Landscape

  • 4.1 Overview
  • 4.2 Europe PEST Analysis
  • 4.3 Expert's Opinion

5. Europe Lung Cancer Screening Market - Key Market Dynamics

  • 5.1 Market Drivers
    • 5.1.1 Rising Lung Cancer Incidences
  • 5.2 Market Restraints
    • 5.2.1 High Cost of Lung Cancer Screening Tests
  • 5.3 Market Opportunities
    • 5.3.1 Structured Lung Cancer Screening Program
  • 5.4 Future Trends
    • 5.4.1 Mobile Lung Cancer Screening Truck
  • 5.5 Impact Analysis

6. Europe Lung Cancer Screening Market - Europe Analysis

  • 6.1 Europe Lung Cancer Screening Market Revenue Forecast and Analysis

7. Europe Lung Cancer Screening Market - Revenue and Forecast to 2028 - By Cancer Type

  • 7.1 Overview
  • 7.2 Europe Lung Cancer Screening Market Revenue Share, by Cancer Type 2022 & 2030 (%)
  • 7.3 Non-Small Cell Lung Cancer (NSCLC)
    • 7.3.1 Overview
    • 7.3.2 Non-Small Cell Lung Cancer (NSCLC): Europe Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Mn)
  • 7.4 Small Cell Lung Cancer
    • 7.4.1 Overview
    • 7.4.2 Small Cell Lung Cancer: Europe Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)

8. Europe Lung Cancer Screening Market Analysis - by Technology

  • 8.1 Overview
  • 8.2 Low-Dose Computed Tomography (LDCT)
    • 8.2.1 Overview
    • 8.2.2 Low-Dose Computed Tomography (LDCT): Europe Lung Cancer Screening Market- Revenue and Forecast to 2030 (US$ Million)
  • 8.3 Chest X-ray
    • 8.3.1 Overview
    • 8.3.2 Chest X-ray: Europe Lung Cancer Screening Market- Revenue and Forecast to 2030 (US$ Million)
  • 8.4 Liquid Biopsy
    • 8.4.1 Overview
    • 8.4.2 Liquid Biopsy: Europe Lung Cancer Screening Market- Revenue and Forecast to 2030 (US$ Million)
  • 8.5 Others
    • 8.5.1 Overview
    • 8.5.2 Others: Europe Lung Cancer Screening Market- Revenue and Forecast to 2030 (US$ Million)

9. Europe Lung Cancer Screening Market Analysis - by Age Group

  • 9.1 Overview
  • 9.2 & Older
    • 9.2.1 Overview
    • 9.2.2 & Older: Australia Lung Cancer Screenings Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.3 Below 50
    • 9.3.1 Overview
    • 9.3.2 Below 50: Lung Cancer Screenings Market - Revenue and Forecast to 2030 (US$ Million)

10. Europe Lung Cancer Screening Market Analysis - by End User

  • 10.1 Overview
  • 10.2 Hospitals
    • 10.2.1 Overview
    • 10.2.2 Hospitals: Lung Cancer Screenings Market - Revenue and Forecast to 2030 (US$ Million)
  • 10.3 Diagnostic Centers
    • 10.3.1 Overview
    • 10.3.2 Diagnostic Centers: Lung Cancer Screenings Market - Revenue and Forecast to 2030 (US$ Million)
  • 10.4 Others
    • 10.4.1 Overview
    • 10.4.2 Others: Lung Cancer Screenings Market - Revenue and Forecast to 2030 (US$ Million)

11. Europe Lung Cancer Screening Market - Revenue and Forecast to 2028 - Country Analysis

  • 11.1 Europe: Europe Lung Cancer Screening Market Overview
      • 11.1.1.1 Germany: Europe Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.1.1.1.1 Overview
        • 11.1.1.1.2 Germany: Europe Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.1.1.1.3 Germany: Europe Lung Cancer Screening Market, by Cancer Type, 2020-2030 (US$ Million)
        • 11.1.1.1.4 Germany: Europe Lung Cancer Screening Market, by Technology - Revenue and Forecast to 2030 (US$ Million)
        • 11.1.1.1.5 Germany: Europe Lung Cancer Screening Market, by Age Group, 2020-2030 (US$ Million)
        • 11.1.1.1.6 Germany: Europe Lung Cancer Screening Market, by End User, 2020-2030 (US$ Million)
      • 11.1.1.2 UK: Europe Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.1.1.2.1 Overview
        • 11.1.1.2.2 UK: Europe Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.1.1.2.3 UK: Europe Lung Cancer Screening Market, by Cancer Type, 2020-2030 (US$ Million)
        • 11.1.1.2.4 UK: Europe Lung Cancer Screening Market, by Technology - Revenue and Forecast to 2030 (US$ Million)
        • 11.1.1.2.5 UK: Europe Lung Cancer Screening Market, by Age Group, 2020-2030 (US$ Million)
        • 11.1.1.2.6 UK: Europe Lung Cancer Screening Market, by End User, 2020-2030 (US$ Million)
      • 11.1.1.3 France: Europe Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.1.1.3.1 Overview
        • 11.1.1.3.2 France: Europe Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.1.1.3.3 France: Europe Lung Cancer Screening Market, by Cancer Type, 2020-2030 (US$ Million)
        • 11.1.1.3.4 France: Europe Lung Cancer Screening Market, by Technology - Revenue and Forecast to 2030 (US$ Million)
        • 11.1.1.3.5 France: Europe Lung Cancer Screening Market, by Age Group, 2020-2030 (US$ Million)
        • 11.1.1.3.6 France: Europe Lung Cancer Screening Market, by End User, 2020-2030 (US$ Million)
      • 11.1.1.4 Italy: Europe Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.1.1.4.1 Overview
        • 11.1.1.4.2 Italy: Europe Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.1.1.4.3 Italy: Europe Lung Cancer Screening Market, by Cancer Type, 2020-2030 (US$ Million)
        • 11.1.1.4.4 Italy: Europe Lung Cancer Screening Market, by Technology - Revenue and Forecast to 2030 (US$ Million)
        • 11.1.1.4.5 Italy: Europe Lung Cancer Screening Market, by Age Group, 2020-2030 (US$ Million)
        • 11.1.1.4.6 Italy: Europe Lung Cancer Screening Market, by End User, 2020-2030 (US$ Million)
      • 11.1.1.5 Spain: Europe Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.1.1.5.1 Overview
        • 11.1.1.5.2 Spain: Europe Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.1.1.5.3 Spain: Europe Lung Cancer Screening Market, by Cancer Type, 2020-2030 (US$ Million)
        • 11.1.1.5.4 Spain: Europe Lung Cancer Screening Market, by Technology - Revenue and Forecast to 2030 (US$ Million)
        • 11.1.1.5.5 Spain: Europe Lung Cancer Screening Market, by Age Group, 2020-2030 (US$ Million)
        • 11.1.1.5.6 Spain: Europe Lung Cancer Screening Market, by End User, 2020-2030 (US$ Million)
      • 11.1.1.6 Rest of Europe: Europe Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.1.1.6.1 Overview
        • 11.1.1.6.2 Rest of Europe: Europe Lung Cancer Screening Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.1.1.6.3 Rest of Europe: Europe Lung Cancer Screening Market, by Cancer Type, 2020-2030 (US$ Million)
        • 11.1.1.6.4 Rest of Europe: Europe Lung Cancer Screening Market, by Technology - Revenue and Forecast to 2030 (US$ Million)
        • 11.1.1.6.5 Rest of Europe: Europe Lung Cancer Screening Market, by Age Group, 2020-2030 (US$ Million)
        • 11.1.1.6.6 Rest of Europe: Europe Lung Cancer Screening Market, by End User, 2020-2030 (US$ Million)

12. Europe Lung Cancer Screening Market-Industry Landscape

  • 12.1 Recent Growth Strategies
    • 12.1.1 Overview

13. Company Profiles

  • 13.1 Intelerad Medical Systems
    • 13.1.1 Key Facts
    • 13.1.2 Business Description
    • 13.1.3 Products and Services
    • 13.1.4 Financial Overview
    • 13.1.5 SWOT Analysis
    • 13.1.6 Key Developments
  • 13.2 Nuance Communications Inc
    • 13.2.1 Key Facts
    • 13.2.2 Business Description
    • 13.2.3 Products and Services
    • 13.2.4 Financial Overview
    • 13.2.5 SWOT Analysis
    • 13.2.6 Key Developments
  • 13.3 GE HealthCare
    • 13.3.1 Key Facts
    • 13.3.2 Business Description
    • 13.3.3 Products and Services
    • 13.3.4 Financial Overview
    • 13.3.5 SWOT Analysis
    • 13.3.6 Key Developments
  • 13.4 Medtronic
    • 13.4.1 Key Facts
    • 13.4.2 Business Description
    • 13.4.3 Products and Services
    • 13.4.4 Financial Overview
    • 13.4.5 SWOT Analysis
    • 13.4.6 Key Developments
  • 13.5 Canon Inc.
    • 13.5.1 Key Facts
    • 13.5.2 Business Description
    • 13.5.3 Products and Services
    • 13.5.4 Financial Overview
    • 13.5.5 SWOT Analysis
    • 13.5.6 Key Developments
  • 13.6 Koninklijke Philips NV
    • 13.6.1 Key Facts
    • 13.6.2 Business Description
    • 13.6.3 Products and Services
    • 13.6.4 Financial Overview
    • 13.6.5 SWOT Analysis
    • 13.6.6 Key Developments
  • 13.7 Siemens AG
    • 13.7.1 Key Facts
    • 13.7.2 Business Description
    • 13.7.3 Products and Services
    • 13.7.4 Financial Overview
    • 13.7.5 SWOT Analysis
    • 13.7.6 Key Developments

14. Appendix

  • 14.1 About The Insight Partners
  • 14.2 Glossary of Terms